CHIARLE, Roberto
CHIARLE, Roberto
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
A Braf kinase-inactive mutant induces lung adenocarcinoma
2017-01-01 Nieto P.; Ambrogio C.; Esteban-Burgos L.; Gomez-Lopez G.; Blasco M.T.; Yao Z.; Marais R.; Rosen N.; Chiarle R.; Pisano D.G.; Barbacid M.; Santamaria D.
A LIBRETTO to orchestrate targeted therapy
2020-01-01 Marmarelis, Melina E; Chiarle, Roberto; Ambrogio, Chiara; Aggarwal, Charu
A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment
2015-01-01 Alberti, Diego; Protti, Nicoletta; Toppino, Antonio; Deagostino, Annamaria; Lanzardo, Stefania; Bortolussi, Silva; Altieri, Saverio; Voena, Claudia; Chiarle, Roberto; Geninatti Crich, Simonetta; Aime, Silvio
Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
2006-01-01 PIVA R; CHIARLE R; MANAZZA AD; TAULLI R; SIMMONS W; AMBROGIO C; D'ESCAMARD V; PELLEGRINO E; PONZETTO C; PALESTRO G; INGHIRAMI G
Advances in cancer immunology and cancer immunotherapy
2016-01-01 Voena, Claudia*; Chiarle, Roberto
ALK inhibitors and vaccination against anaplastic lymphoma kinase (ALK) induce potent anti-tumor activity improving survival in non small cell lung carcinoma (NSCLC)
2012-01-01 C. Voena; M. Menotti; C. Mastini; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; F. Cavallo; G. Inghirami; R. Chiarle
ALK protein tyrosine kinase, cells and methods embodying and using same
2005-01-01 R. Chiarle; G. Inghirami
ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis
2014-01-01 Martinengo, Cinzia; Poggio, Teresa; Menotti, Matteo; Scalzo, Maria Stella; Mastini, Cristina; Ambrogio, Chiara; Pellegrino, Elisa; Riera, Ludovica; Piva, Roberto; Ribatti, Domenico; Pastorino, Fabio; Perri, Patrizia; Ponzoni, Mirco; Wang, Qi; Voena, Claudia; Chiarle, Roberto
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors
2008-01-01 P. ACCORNERO; G. LATTANZIO; T. MANGANO; R. CHIARLE; R. TAULLI; F. BERSANI; P.E. FORNI; S. MIRETTI; C. SCUOPPO; W. DASTRU; J. CHRISTENSEN; T. CREPALDI; C. PONZETTO
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma associated antigen
2009-01-01 P. Cappello; B Tomaino; R. Chiarle; P. Ceruti; A. Novarino; C. Castagnoli; P. Migliorini; G. Perconti; A. Giallongo; M. Milella; V. Monsurrò; S. Barbi; A. Scarpa; P. Nisticò; M. Giovarelli; F. Novelli
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
2009-01-01 Fornari A; Piva R; Chiarle R; Novero D; Inghirami G
Anaplastic large-cell lymphoma
2011-01-01 Inghirami G; Pileri SA; Chiarle R; Cuccuru G; Martinoglio B; Medico E; Pellegrino E; Piva R; Ruberto ML; Fornari A; Novero D; Chilosi M; Zamó A; Facchetti F; Lonardi S; De Chiara A; Fulciniti F; Doglioni C; Ponzoni M; Agnelli L; Neri A; Todoerti K; Agostinelli C; Piccaluga PP; Falini B; Tiacci E; Van Loo P; Tousseyn T; De Wolf-Peeters C; Geissinger E; Muller-Hermelink HK; Rosenwald A; Piris MA; Rodriguez ME.
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
2002-01-01 ZAMO A; R. CHIARLE; PIVA R; HOWES J; FAN Y; CHILOSI M; LEVY DE; INGHIRAMI G.
Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination
2007-01-01 R. Chiarle; G. Inghirami; G. Forni
Anaplastic lymphoma kinase: an oncogene for tumor vaccination
2009-01-01 Mastini C; Martinengo C; Inghirami G; Chiarle R.
Argyrophilic nucleolar organizer region counts predict survival in thymoma.
1994-01-01 PICH A ;CHIARLE R ;CHIUSA L ;PALESTRO G
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.
2013-01-01 Capello M; Cappello P; Linty FC; Chiarle R; Sperduti I; Novarino A; Salacone P; Mandili G; Naccarati A; Sacerdote C; Beghelli S; Bersani S; Barbi S; Bassi C; Scarpa A; Nisticò P; Giovarelli M; Vineis P; Milella M; Novelli F.
Autoantibody signature in human ductal pancreatic adenocarcinoma
2007-01-01 TOMAINO B; CAPPELLO P; CAPELLO M; FREDOLINI C; PONZETTO A; NOVARINO A; CIUFFREDA L; BERTETTO O; ANGELIS CD; GAIA E; SALACONE P; MILELLA M; NISTICO P; ALESSIO M; CHIARLE R; GIUFFRIDA MG; GIOVARELLI M; NOVELLI F
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma
2003-01-01 BONELLO L; VOENA C; LADETTO M; BOCCADORO M; PALESTRO G; INGHIRAMI G; R. CHIARLE
Calming down T cell acute leukemia.
2012-01-01 Hirsch E;Chiarle R
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Braf kinase-inactive mutant induces lung adenocarcinoma | 2017 | Nieto P.; Ambrogio C.; Esteban-Burgos L.; Gomez-Lopez G.; Blasco M.T.; Yao Z.; Marais R.; Rosen N.; Chiarle R.; Pisano D.G.; Barbacid M.; Santamaria D. | |
| A LIBRETTO to orchestrate targeted therapy | 2020 | Marmarelis, Melina E; Chiarle, Roberto; Ambrogio, Chiara; Aggarwal, Charu | |
| A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment | 2015 | Alberti, Diego; Protti, Nicoletta; Toppino, Antonio; Deagostino, Annamaria; Lanzardo, Stefania; Bortolussi, Silva; Altieri, Saverio; Voena, Claudia; Chiarle, Roberto; Geninatti Crich, Simonetta; Aime, Silvio | |
| Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas | 2006 | PIVA R; CHIARLE R; MANAZZA AD; TAULLI R; SIMMONS W; AMBROGIO C; D'ESCAMARD V; PELLEGRINO E; PONZETTO C; PALESTRO G; INGHIRAMI G | |
| Advances in cancer immunology and cancer immunotherapy | 2016 | Voena, Claudia*; Chiarle, Roberto | |
| ALK inhibitors and vaccination against anaplastic lymphoma kinase (ALK) induce potent anti-tumor activity improving survival in non small cell lung carcinoma (NSCLC) | 2012 | C. Voena; M. Menotti; C. Mastini; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; F. Cavallo; G. Inghirami; R. Chiarle | |
| ALK protein tyrosine kinase, cells and methods embodying and using same | 2005 | R. Chiarle; G. Inghirami | |
| ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis | 2014 | Martinengo, Cinzia; Poggio, Teresa; Menotti, Matteo; Scalzo, Maria Stella; Mastini, Cristina; Ambrogio, Chiara; Pellegrino, Elisa; Riera, Ludovica; Piva, Roberto; Ribatti, Domenico; Pastorino, Fabio; Perri, Patrizia; Ponzoni, Mirco; Wang, Qi; Voena, Claudia; Chiarle, Roberto | |
| An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors | 2008 | P. ACCORNERO; G. LATTANZIO; T. MANGANO; R. CHIARLE; R. TAULLI; F. BERSANI; P.E. FORNI; S. MIRETTI; C. SCUOPPO; W. DASTRU; J. CHRISTENSEN; T. CREPALDI; C. PONZETTO | |
| An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma associated antigen | 2009 | P. Cappello; B Tomaino; R. Chiarle; P. Ceruti; A. Novarino; C. Castagnoli; P. Migliorini; G. Perconti; A. Giallongo; M. Milella; V. Monsurrò; S. Barbi; A. Scarpa; P. Nisticò; M. Giovarelli; F. Novelli | |
| Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? | 2009 | Fornari A; Piva R; Chiarle R; Novero D; Inghirami G | |
| Anaplastic large-cell lymphoma | 2011 | Inghirami G; Pileri SA; Chiarle R; Cuccuru G; Martinoglio B; Medico E; Pellegrino E; Piva R; Ruberto ML; Fornari A; Novero D; Chilosi M; Zamó A; Facchetti F; Lonardi S; De Chiara A; Fulciniti F; Doglioni C; Ponzoni M; Agnelli L; Neri A; Todoerti K; Agostinelli C; Piccaluga PP; Falini B; Tiacci E; Van Loo P; Tousseyn T; De Wolf-Peeters C; Geissinger E; Muller-Hermelink HK; Rosenwald A; Piris MA; Rodriguez ME. | |
| Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death | 2002 | ZAMO A; R. CHIARLE; PIVA R; HOWES J; FAN Y; CHILOSI M; LEVY DE; INGHIRAMI G. | |
| Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination | 2007 | R. Chiarle; G. Inghirami; G. Forni | |
| Anaplastic lymphoma kinase: an oncogene for tumor vaccination | 2009 | Mastini C; Martinengo C; Inghirami G; Chiarle R. | |
| Argyrophilic nucleolar organizer region counts predict survival in thymoma. | 1994 | PICH A ;CHIARLE R ;CHIUSA L ;PALESTRO G | |
| Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. | 2013 | Capello M; Cappello P; Linty FC; Chiarle R; Sperduti I; Novarino A; Salacone P; Mandili G; Naccarati A; Sacerdote C; Beghelli S; Bersani S; Barbi S; Bassi C; Scarpa A; Nisticò P; Giovarelli M; Vineis P; Milella M; Novelli F. | |
| Autoantibody signature in human ductal pancreatic adenocarcinoma | 2007 | TOMAINO B; CAPPELLO P; CAPELLO M; FREDOLINI C; PONZETTO A; NOVARINO A; CIUFFREDA L; BERTETTO O; ANGELIS CD; GAIA E; SALACONE P; MILELLA M; NISTICO P; ALESSIO M; CHIARLE R; GIUFFRIDA MG; GIOVARELLI M; NOVELLI F | |
| BRAF gene is not mutated in plasma cell leukemia and multiple myeloma | 2003 | BONELLO L; VOENA C; LADETTO M; BOCCADORO M; PALESTRO G; INGHIRAMI G; R. CHIARLE | |
| Calming down T cell acute leukemia. | 2012 | Hirsch E;Chiarle R |